BACKGROUND: Treatment guidelines recommend all HIV/HCV-co-infected persons be considered for hepatitis C virus (HCV) treatment, yet obstacles to testing and accessing treatment for HCV continue for women. OBJECTIVE: To assess awareness of HCV, and describe diagnostic referrals and HCV treatment among women in the Women's Interagency HIV Study (WIHS). DESIGN: Prospective epidemiologic cohort. PARTICIPANTS: Of 3,768 HIV-infected and uninfected women in WIHS, 1,166 (31%) were HCV antibody positive. MEASUREMENTS AND MAIN RESULTS: Awareness of HCV infection and probability of referrals for diagnostic evaluations and treatment using logistic regression. Follow-up HCV information was available for 681 (390 died, 15 withdrew, 80 missed visit) in 2004. Of these 681, 522 (76.7%) reported knowing their HCV diagnosis. Of these, 247 of 522 (47.3%) stated their providers recommended a liver biopsy, whereas 139 of 247 or 56.3% reported having a liver biopsy. A total of 170 of 522 (32.6%) reported being offered treatment and 74.1% (n = 126 of 170) reported receiving HCV treatment. In multivariate regression analyses, African-American race, Hispanic/Latina ethnicity, poverty, and current crack/cocaine/heroin use were negatively associated with treatment referrals, whereas elevated alanine aminotransferase (ALT) was associated with increased likelihood of referral and increased likelihood of treatment. CONCLUSION: One quarter of women with HCV in this cohort were not aware of their diagnosis. Among those aware of their HCV, 1 in 4 received liver biopsy and treatment for HCV. Both provider and patient education interventions regarding HCV testing and HCV treatment options and guidelines are needed to enhance HCV awareness and participation in HCV evaluation and treatment.
BACKGROUND: Treatment guidelines recommend all HIV/HCV-co-infectedpersons be considered for hepatitis C virus (HCV) treatment, yet obstacles to testing and accessing treatment for HCV continue for women. OBJECTIVE: To assess awareness of HCV, and describe diagnostic referrals and HCV treatment among women in the Women's Interagency HIV Study (WIHS). DESIGN: Prospective epidemiologic cohort. PARTICIPANTS: Of 3,768 HIV-infected and uninfected women in WIHS, 1,166 (31%) were HCV antibody positive. MEASUREMENTS AND MAIN RESULTS: Awareness of HCV infection and probability of referrals for diagnostic evaluations and treatment using logistic regression. Follow-up HCV information was available for 681 (390 died, 15 withdrew, 80 missed visit) in 2004. Of these 681, 522 (76.7%) reported knowing their HCV diagnosis. Of these, 247 of 522 (47.3%) stated their providers recommended a liver biopsy, whereas 139 of 247 or 56.3% reported having a liver biopsy. A total of 170 of 522 (32.6%) reported being offered treatment and 74.1% (n = 126 of 170) reported receiving HCV treatment. In multivariate regression analyses, African-American race, Hispanic/Latina ethnicity, poverty, and current crack/cocaine/heroin use were negatively associated with treatment referrals, whereas elevated alanine aminotransferase (ALT) was associated with increased likelihood of referral and increased likelihood of treatment. CONCLUSION: One quarter of women with HCV in this cohort were not aware of their diagnosis. Among those aware of their HCV, 1 in 4 received liver biopsy and treatment for HCV. Both provider and patient education interventions regarding HCV testing and HCV treatment options and guidelines are needed to enhance HCV awareness and participation in HCV evaluation and treatment.
Authors: Farzana Kapadia; Mary H Latka; Holly Hagan; Elizabeth T Golub; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; David L Thomas; Sebastian Bonner; Thelma Thiel; Steffanie A Strathdee Journal: J Urban Health Date: 2007-01 Impact factor: 3.671
Authors: Astrid Knott; Eric Dieperink; Mark L Willenbring; Sara Heit; Janet M Durfee; Mary Wingert; James R Johnson; Paul Thuras; Samuel B Ho Journal: Am J Gastroenterol Date: 2006-10 Impact factor: 10.864
Authors: Rainer Weber; Caroline A Sabin; Nina Friis-Møller; Peter Reiss; Wafaa M El-Sadr; Ole Kirk; Francois Dabis; Matthew G Law; Christian Pradier; Stephane De Wit; Börje Akerlund; Gonzalo Calvo; Antonella d'Arminio Monforte; Martin Rickenbach; Bruno Ledergerber; Andrew N Phillips; Jens D Lundgren Journal: Arch Intern Med Date: 2006 Aug 14-28
Authors: M Augenbraun; J J Goedert; D Thomas; J Feldman; E C Seaberg; A L French; E Robison; M Nowicki; N Terrault Journal: Clin Infect Dis Date: 2003-10-14 Impact factor: 9.079
Authors: Ann Drobnik; Caroline Judd; David Banach; Joseph Egger; Kevin Konty; Eric Rude Journal: Am J Public Health Date: 2011-09-22 Impact factor: 9.308
Authors: Jeffrey J Weiss; Georgina Osorio; Elizabeth Ryan; Sue M Marcus; Dawn A Fishbein Journal: AIDS Patient Care STDS Date: 2010-01 Impact factor: 5.078
Authors: Judith Tsui; Eric Vittinghoff; Kathryn Anastos; Michael Augenbraun; Mary Young; Marek Nowicki; Mardge H Cohen; Marion G Peters; Elizabeth T Golub; Lynda Szczech Journal: Am J Kidney Dis Date: 2009-04-25 Impact factor: 8.860
Authors: Andrea D Branch; Mark L Van Natta; Marie-Louise Vachon; Douglas T Dieterich; Curtis L Meinert; Douglas A Jabs Journal: Clin Infect Dis Date: 2012-04-24 Impact factor: 9.079
Authors: Peter E Mangesho; Joanna Reynolds; Martha Lemnge; Lasse S Vestergaard; Clare I R Chandler Journal: Malar J Date: 2014-12-13 Impact factor: 2.979